Physician profile
Lin Gao
NPI 1588078299
$5,982.46
in general payments reported to CMS, 2019-2025
28 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $136 · 2021: $1,481 · 2022: $697 · 2023: $1,302 · 2024: $1,056 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $782.02 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $779.59 | 2021-2025 | Farxiga, Lokelma, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $426.86 | 2020-2025 | Camzyos, Eliquis |
| Amgen INC. | $360.53 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $358.76 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $347.35 | 2021-2025 | |
| Pfizer INC. | $311.89 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $257.50 | 2023-2024 | Tarpeyo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.58 | 2020-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $232.00 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.63 | 2023-2025 | Jardiance |
| Abbott Laboratories | $172.57 | 2024 | |
| Novo Nordisk INC | $171.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $169.62 | 2024-2025 | Impella |
| Elutia, INC. | $163.37 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $142.29 | 2021 | |
| Cleerly, INC. | $130.76 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $117.39 | 2021 | |
| Abbvie INC. | $117.19 | 2022 | |
| Impel Pharmaceuticals INC. | $114.92 | 2022 | |
| Heartflow, INC. | $71.52 | 2023-2025 | Ffrct |
| Cvrx, INC. | $47.75 | 2024-2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $42.87 | 2025 | Inspire |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Edwards Lifesciences Corporation | $39.59 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $24.36 | 2025 | Tryngolza |
| Actelion Pharmaceuticals US, INC. | $14.95 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.